Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Roschewski Website

Mark J. Roschewski, M.D.

Selected Publications

1)  Roschewski M, Korde N, Wu SP, Landgren O.
Pursuing the curative blueprint for early myeloma.
Blood. 122: 486-90, 2013.
2)  Roschewski M, Farooqui M, Aue G, Wilhelm F, Wiestner A.
Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies.
Leukemia. 27: 1920-3, 2013.
3)  Roschewski M, Dunleavy K, Wilson WH.
Diffuse large B cell lymphoma: molecular targeted therapy.
Int. J. Hematol. 96: 552-61, 2012.
4)  Roschewski M, Wilson WH.
Biology and management of rare primary extranodal T-cell lymphomas.
Oncology (Williston Park, N.Y.). 24: 94-100, 2010.
5)  Roschewski M, Wilson WH.
EBV-associated lymphomas in adults.
Best Pract Res Clin Haematol. 25: 75-89, 2012.
6)  Roschewski M, Wilson WH.
Lymphomatoid granulomatosis.
Cancer J. 18: 469-74, 2012.
7)  Chapman CM, Sun X, Roschewski M, Aue G, Farooqui M, Stennett L, Gibellini F, Arthur D, Pérez-Galán P, Wiestner A.
ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress.
Clin. Cancer Res. 18: 1979-91, 2012.
8)  Cherry BM, Korde N, Kwok M, Roschewski M, Landgren O.
Evolving therapeutic paradigms for multiple myeloma: back to the future.
Leuk. Lymphoma. 54: 451-63, 2013.
9)  Cherry BM, Korde N, Kwok M, Manasanch EE, Bhutani M, Mulquin M, Zuchlinski D, Yancey MA, Maric I, Calvo KR, Braylan R, Stetler-Stevenson M, Yuan C, Tembhare P, Zingone A, Costello R, Roschewski MJ, Landgren O.
Modeling progression risk for smoldering multiple myeloma: results from a prospective clinical study.
Leuk. Lymphoma. [Epub ahead of print], 2013.
10)  Davidson-Moncada JK, McDuffee E, Roschewski M.
CD5+ diffuse large B-cell lymphoma with hemophagocytosis.
J. Clin. Oncol. 31: e76-9, 2013.
11)  Lai C, Roschewski M.
Nodal marginal zone lymphoma: impersonalized medicine.
Oncology (Williston Park, N.Y.). 26: 104, 106, 108, 2012.
12)  Dunleavy K, Roschewski M, Wilson WH.
Lymphomatoid granulomatosis and other Epstein-Barr virus associated lymphoproliferative processes.
Curr Hematol Malig Rep. 7: 208-15, 2012.
13)  Cherry BM, Costello R, Zingone A, Burris J, Korde N, Manasanch E, Kwok M, Annunziata C, Roschewski MJ, Engels EA, Landgren O.
Immunoparesis and monoclonal gammopathy of undetermined significance are disassociated in advanced age.
Am. J. Hematol. 88: 89-92, 2013.
14)  Brown G, Shapeero LG, Weiss BM, Roschewski M.
Multiple myeloma with lacrimal gland amyloidosis and sarcoidosis.
Am. J. Hematol. 85: 506-9, 2010.
15)  Gilstad C, Roschewski M, Wells J, Delmas A, Lackey J, Uribe P, Popa C, Jardeleza T, Roop S.
Fatal transfusion-associated graft-versus-host disease with concomitant immune hemolysis in a group A combat trauma patient resuscitated with group O fresh whole blood.
Transfusion. 52: 930-5, 2012.
Click Here to View Collapsed Bibliography.

This page was last updated on 4/11/2014.